Mitochondria-containing large extracellular vesicles target mouse motor neurons upon intramuscular injection

Paromita Paul Pinky, Zhongmin Wang, Purva Khare, Jhanvi R Jhaveri, Vivek Basudkar, K Rama Rao, Andrea D. Lawrence, Adithri Pingali, Kandarp M. Dave, Donna B. Stolz, Ming Sun, Siyang Zheng, Sruti Shiva, Carol Milligan, Osvaldo Delbono, Devika S. ManickambioRxiv 2025 · DOI

TL;DR

This study investigates extracellular vesicles (EVs) derived from motor neuron-like cells as a potential therapy for Amyotrophic Lateral Sclerosis (ALS). They found that larger EVs (lEVs) carry functional mitochondria and can deliver them to motor neurons, improving their function and survival in a heat-stress model of ALS. This suggests a novel therapeutic avenue for ALS by leveraging mitochondria-containing EVs.

What Problem Does This Paper Address?

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive loss of motor neurons. A key hallmark of ALS pathology is mitochondrial dysfunction, which exacerbates neurodegeneration. Current ALS treatments offer only modest benefits, highlighting an urgent need for novel therapeutic strategies. This paper explores the potential of extracellular vesicles (EVs), specifically those derived from neurons, as a delivery vehicle for functional mitochondria to combat mitochondrial dysfunction in motor neurons, a central issue in ALS.

Methods

The researchers utilized a combination of cell culture, molecular biology, and in vivo techniques. They employed a motor neuron-like cell line (NSC-34) and differentiated it into motor neurons (dNSC-34) to serve as a source of EVs. EVs were isolated using differential ultracentrifugation, and characterized by dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), and transmission electron microscopy (TEM). Mitochondrial transfer was assessed using MitoTracker Red staining, flow cytometry, and fluorescence microscopy. Cell viability was measured using the MTT assay, and mitochondrial function was evaluated using the Seahorse assay to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). An in vivo pilot study involved intramuscular injection of labeled EVs into mice to track their delivery to spinal cord motor neurons.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • lEVs, not sEVs, carry mitochondria: A crucial finding is that only larger extracellular vesicles (lEVs) derived from neuronal cells contained intact mitochondria, while smaller EVs (sEVs) did not. This distinction is vital for understanding their therapeutic potential.
  • Neuronal EVs improve motor neuron function: Treatment with both lEVs and sEVs improved the viability and oxygen consumption of heat-stressed motor neurons, suggesting a general beneficial effect of neuronal EVs. However, lEVs showed a more efficient improvement in oxidative phosphorylation, likely due to their mitochondrial cargo.
  • Mitochondria transfer in vivo: The study successfully demonstrated that mitochondria-containing lEVs can be delivered to motor neurons in the spinal cord of mice after intramuscular injection, highlighting the potential for in vivo therapeutic application.
  • Dose-dependent delivery: The uptake of labeled mitochondria by motor neurons in vivo was dose-dependent, with a medium dose showing effective neuronal labeling.

Key Results

  • Cell Viability: dNSC-34 derived lEVs and sEVs significantly improved cell viability in heat-stressed neurons compared to EVs from undifferentiated NSC-34 cells. For example, treatment with 100 µg of dNSC-34-lEVs increased cell viability to 85%, compared to 32% in untreated heat-stressed neurons.
  • Mitochondrial Function: Seahorse assay results showed that both lEVs and sEVs increased basal and maximal oxygen consumption rates (OCR) in heat-stressed neurons. Notably, lEV treatment resulted in a lower proton leak, suggesting more efficient oxidative phosphorylation compared to sEVs.
  • In Vivo Delivery: Intramuscular injection of MitoT-labeled lEVs into mice resulted in the delivery of labeled mitochondria to lumbar spinal cord motor neurons, with clear colocalization observed in ChAT-GFP positive motor neurons.

Limitations and Future Work

  • sEVs' mechanism: While sEVs improved cell viability and respiration, they did not contain mitochondria. The authors suggest that mitochondrial components like mtDNA and proteins, or heat shock proteins (HSPs) present in sEVs, might be responsible for these effects, warranting further investigation into their molecular cargo.
  • Proteomic profiling: Future studies will focus on proteomic profiling of neuronal sEVs and lEVs to elucidate the differences in their molecular and mitochondrial cargo.
  • ALS model: The study proposes to apply this EV-based therapeutic approach to the SOD1G93A transgenic mouse model of ALS to evaluate its therapeutic efficacy.
  • EV source: While NSC-34 cells were used as a surrogate, future studies could explore EVs derived directly from primary motor neurons.

Summary updated

Abstract

Abstract Amyotrophic Lateral Sclerosis ( ALS ) is a neurological disorder that causes progressive degeneration of motor neurons. Mitochondrial dysfunction accelerates neurodegeneration aggravating the severity of ALS. We hypothesized that increasing the mitochondrial function of motor neurons may promote neuronal survival. Therefore, we investigated the potential of neuron-derived mitochondria containing extracellular vehicles ( EVs ) as a novel therapeutic approach for ALS using differentiated NSC-34 cells as a surrogate for neurons. Neuron derived-large EVs ( lEVs ) but not small EVs ( sEVs ) contained mitochondria. However, we observed increased cell viability and oxygen consumption rates in heat-stressed neurons treated with both sEVs and lEVs suggesting improved mitochondrial function in recipient neurons. The increased oxygen consumption rates in sEV-treated heat-stressed neurons was accompanied by a greater proton leak compared to lEV treatment. The greater proton leak observed with sEVs likely suggests a lower efficiency of oxidative phosphorylation compared to that achieved by cells treated with mitochondria-containing lEVs. These findings suggest that mitochondrial components present in sEVs, such as proteins and mitochondrial DNA, may too contribute to improving cellular respiration. Furthermore, we have demonstrated that lEV mitochondria are transported into the lumbar spinal cord motor neurons following intramuscular injection in C57BL/6 mice in a EV dose-dependent manner. Collectively, for the first time, we have demonstrated the therapeutic effects of neuronal EVs in recipient heat-stressed neurons and the delivery of lEV mitochondria to spinal cord motor neurons in vivo without any EV surface modifications for neuronal targeting. Further studies will determine the therapeutic efficacy of mitochondria-containing EVs in the SOD1 G93A transgenic mouse model of ALS. Graphical abstract
BibTeX
@misc{pinky2025mitochondria,
  author = {Paromita Paul Pinky and Zhongmin Wang and Purva Khare and Jhanvi R Jhaveri and Vivek Basudkar and K Rama Rao and Andrea D. Lawrence and Adithri Pingali and Kandarp M. Dave and Donna B. Stolz and Ming Sun and Siyang Zheng and Sruti Shiva and Carol Milligan and Osvaldo Delbono and Devika S. Manickam},
  title = {{Mitochondria-containing large extracellular vesicles target mouse motor neurons upon intramuscular injection}},
  year = {2025},
  doi = {10.1101/2025.09.15.675842},
  howpublished = {bioRxiv},
}
Figure